Mustafa B.
- Country
- Germany
- Department
- Facharztpraxis für Innere Medizin, Nierenheilkunde und Bluthochdruckkrankheiten
Research Overview
- Efficacy and Safety of Baxdrostat and Dapagliflozin on Renal and Cardiovascular Outcomes in Chronic Kidney Disease with Hypertension
- Evaluation of Vicadrostat and Empagliflozin in Simultaneous vs. Staggered Initiation for Chronic Kidney Disease Progression Risk
- Evaluation of Vicadrostat (BI 690517) and Empagliflozin Efficacy and Safety in Type 2 Diabetes, Hypertension, and Cardiovascular Disease Patients
Data & Insights
Has run more than one trial at 66 of 588 partner sites.
Specializations
Nephrology
The investigator specializes in treating patients with chronic kidney disease (CKD), focusing on innovative therapeutic approaches for renal function preservation and disease management.
- Kidney Function Monitoring
- Renal Disease Progression
- eGFR Assessment
Their research encompasses comprehensive evaluation of kidney function markers and disease progression indicators.
Cardiovascular Health
The investigator concentrates on cardiovascular complications associated with kidney disease, particularly exploring therapeutic interventions for patients with concurrent conditions.
- Cardiovascular Risk Management
- Blood Pressure Control
- Cardiovascular Outcomes
Their work addresses the complex relationship between cardiac and renal health in chronic disease states.
Therapeutic Innovation
The investigator evaluates novel therapeutic combinations for treating patients with hypertension and kidney disease, focusing on medication efficacy and safety profiles.
- Combined Treatment Approaches
- Disease Management Strategies
- Treatment Optimization
Their expertise extends to assessing innovative therapeutic interventions for complex renal conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.